CA2238271C - Pharmaceutical compositions comprising flurbiprofen - Google Patents
Pharmaceutical compositions comprising flurbiprofen Download PDFInfo
- Publication number
- CA2238271C CA2238271C CA002238271A CA2238271A CA2238271C CA 2238271 C CA2238271 C CA 2238271C CA 002238271 A CA002238271 A CA 002238271A CA 2238271 A CA2238271 A CA 2238271A CA 2238271 C CA2238271 C CA 2238271C
- Authority
- CA
- Canada
- Prior art keywords
- flurbiprofen
- dosage form
- solid dosage
- patient
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The present invention relates to the use of flurbiprofen in the treatment of sore throats which comprises the administration to a patient in need of such treatment of a pharmaceutical composition in the form of a masticable or suckable solid dosage form or a spray containing a therapeutically effective amount of flurbiprofen which releases the flurbiprofen in the oral cavity so as to deliver the flurbiprofen to the surface of the sore throat.
Description
MCCARTHY TETRAULT FILE: 008283-231146 APPLICANT: THE BOOTS COMPANY PLC
INVENTORS: DAVID MICHAEL BARRETT
CARL SIMON SMITH
DAVID MICHAEL THURGOOD
TITLE: PHARMACEUTICAL COMPOSITIONS
C:OMPRISING FLURBIPROFEN
pHARMACEUTICAL COMPOSITIONS COMPRISING FLURBIPROFEN
The present invention relates to a new medical use of flurbiprofen.
Flurbiprofen [2-(2-fluoro-4-biphenylyl)propionic] acid is a well. known non-steroidal anti-inflammatory drug which also has analgesic and antipyretic activity. The flurbiprofen molecule exists in two enantiomeric forms and the term flurbiprofen as used herein is intended to embrace the individual enantiomers and mixtures thereof in any proportion including a 1:1 mixture which is herein referred to as racemic flurbiprofen. Flurbiprofen can exist in the form of pharmaceutically acceptable salts or in the form of derivatives such as esters and such salts or esters are embraced by the term "flurbiprofen" as used herein.
Flurbiprofen and its S(+) enantiomer have been proposed for treating medical conditions of the gums.
EP 137668-A (Upjohn) describes the use of flurbiprofen for preventing or inhibiting alveolar bone resorption.
EP 486561-A (Sepracor) describes the use of S(+)-flurbiprofen to treat periodontal disease and to promote bone regrowth associated with the disease. Periodontal disease is stated to include periodontitis, gingivitis and periodontosis.
Both these documents specifically describe the treatment of the gums and do not relate to any other part of the oral cavity.
One aspect of the present invention provides a suckable solid dosage form comprising 2.5 to 20mg of flurbiprofen contained in a lozenge base formed by cooling a sugar-based or sugar alcohol-based molten mass, such that when the dosage form is administered to the oral cavity of a patent in need.
thereof and sucked the solid dosage form releases a therapeutically effective amount of flurbiprofen to the oral cavity so as deliver said flurbiprofen to the surface of the throat of said patient for the treatment of sore throat.
A further aspect of the present invention relates to the use of a pharmaceutical composition in the form of a suckable solid dosage form comprising 2.5 to 20 mg of flurbiprofen formed by cooling a sugar-based or sugar alcohol-based molten mass containing the flurbiprofen, in the manufacture of a medicament for treating sore throat so that on administering the dosage form to the oral cavity of a patient in need thereof, the solid dosage form releases a therapeutically effective amount of flurbiprofen to the oral cavity so as to deliver said flurbiprofen to the surface of the throat of said patient.
The solid dosage form preferably comprises 5 to 12.5 flurbiprofen.
The solid dosage form may be a lozenge. The term "lozenge" as used herein is intended to embrace all dosage forms where the product is formed by cooling a sugar-based or sugar alcohol based (eg sorbitol) molten mass containing the active material.
A preferred solid dosage form is a lozenge prepared by cooling a heated lozenge base comprising sugar, liquid glucose, flurbiprofen and other excipients to form solid lozenges.
The therapeutically effective amount has been found to be from 5% to 40% of the normal adult dose when given by ingestion to achieve a systemic anti-inflammatory and/or analgesic effect. Flurbiprofen may therefore be present in the pharmaceutical composition in an amount from 2.5 to 20 mg preferably 5 to 12.5 mg. Where a pharmaceutically acceptable salt of flurbiprofen is used, the amount of the salt used should be such as to provide the desired amount of flurbiprofen. Suitable salts include the alkali metal salts eg the sodium salt or amino acid salts eg the lysine, arginine or megiumine salts of flurbiprofen.
INVENTORS: DAVID MICHAEL BARRETT
CARL SIMON SMITH
DAVID MICHAEL THURGOOD
TITLE: PHARMACEUTICAL COMPOSITIONS
C:OMPRISING FLURBIPROFEN
pHARMACEUTICAL COMPOSITIONS COMPRISING FLURBIPROFEN
The present invention relates to a new medical use of flurbiprofen.
Flurbiprofen [2-(2-fluoro-4-biphenylyl)propionic] acid is a well. known non-steroidal anti-inflammatory drug which also has analgesic and antipyretic activity. The flurbiprofen molecule exists in two enantiomeric forms and the term flurbiprofen as used herein is intended to embrace the individual enantiomers and mixtures thereof in any proportion including a 1:1 mixture which is herein referred to as racemic flurbiprofen. Flurbiprofen can exist in the form of pharmaceutically acceptable salts or in the form of derivatives such as esters and such salts or esters are embraced by the term "flurbiprofen" as used herein.
Flurbiprofen and its S(+) enantiomer have been proposed for treating medical conditions of the gums.
EP 137668-A (Upjohn) describes the use of flurbiprofen for preventing or inhibiting alveolar bone resorption.
EP 486561-A (Sepracor) describes the use of S(+)-flurbiprofen to treat periodontal disease and to promote bone regrowth associated with the disease. Periodontal disease is stated to include periodontitis, gingivitis and periodontosis.
Both these documents specifically describe the treatment of the gums and do not relate to any other part of the oral cavity.
One aspect of the present invention provides a suckable solid dosage form comprising 2.5 to 20mg of flurbiprofen contained in a lozenge base formed by cooling a sugar-based or sugar alcohol-based molten mass, such that when the dosage form is administered to the oral cavity of a patent in need.
thereof and sucked the solid dosage form releases a therapeutically effective amount of flurbiprofen to the oral cavity so as deliver said flurbiprofen to the surface of the throat of said patient for the treatment of sore throat.
A further aspect of the present invention relates to the use of a pharmaceutical composition in the form of a suckable solid dosage form comprising 2.5 to 20 mg of flurbiprofen formed by cooling a sugar-based or sugar alcohol-based molten mass containing the flurbiprofen, in the manufacture of a medicament for treating sore throat so that on administering the dosage form to the oral cavity of a patient in need thereof, the solid dosage form releases a therapeutically effective amount of flurbiprofen to the oral cavity so as to deliver said flurbiprofen to the surface of the throat of said patient.
The solid dosage form preferably comprises 5 to 12.5 flurbiprofen.
The solid dosage form may be a lozenge. The term "lozenge" as used herein is intended to embrace all dosage forms where the product is formed by cooling a sugar-based or sugar alcohol based (eg sorbitol) molten mass containing the active material.
A preferred solid dosage form is a lozenge prepared by cooling a heated lozenge base comprising sugar, liquid glucose, flurbiprofen and other excipients to form solid lozenges.
The therapeutically effective amount has been found to be from 5% to 40% of the normal adult dose when given by ingestion to achieve a systemic anti-inflammatory and/or analgesic effect. Flurbiprofen may therefore be present in the pharmaceutical composition in an amount from 2.5 to 20 mg preferably 5 to 12.5 mg. Where a pharmaceutically acceptable salt of flurbiprofen is used, the amount of the salt used should be such as to provide the desired amount of flurbiprofen. Suitable salts include the alkali metal salts eg the sodium salt or amino acid salts eg the lysine, arginine or megiumine salts of flurbiprofen.
Flurbiprofen would be expected, in common with other non-steroidal anti-inflammatory agents, to cause an unpleasant burning sensation at the back of the mouth when retained in the mouth. This would clearly be unacceptable to the patient being treated. The present applicants have surprisingly found that an unacceptable burning sensation is not experienced when the present invention is used to treat a sore throat but that the patient does receive relief of the symptoms of the sore throat.
Solid dosage forms may be prepared by methods which are well known in the art for the production of lozenges and may contain other ingredients known in such dosage forms such as acidity regulators, opacifiers, stabilising agents, buffering agents, flavourings, sweeteners, colouring agents, and preservatives. For example, the preferred solid formulations of the present invention may be prepared as lozenges by heating the lozenge base (eg a mixture of sugar and liquid glucose) under vacuum to remove excess water and the remaining components are then blended into the mixture. The resulting mixture is then drawn into a continuous cylindrical mass from which the individual lozenges are formed. The lozenges are then cooled, subjected to a visual check and packed into suitable packaging. One form of suitable packaging is a blister pack of a water-impermeable plastics material (eg polyvinylchloride) closed by a metallic eg aluminium foil. The patient removes the lozenge by applying pressure to the blister to force the lozenge to rupture and pass through the metal foil seal. Lozenges will normally be sucked by the patient to release the flurbiprofen.
The preferred formulations for use in the present invention are compositions which can be sucked by the patient and which slowly release the flurbiprofen. The flurbiprofen then passes over the mucous membrane of the throat where some is absorbed providing topical relief. The unabsorbed flurbiprofen is then ingested by the patient and absorbed into the blood stream.
The flurbiprofen so absorbed can act systematically to provide analgesia, anti-inflammatory and anti-pyretic activity in addition to the relief that comes from the topical application of flurbiprofen to the mucous membrane of the throat.
Solid dosage forms may be prepared by methods which are well known in the art for the production of lozenges and may contain other ingredients known in such dosage forms such as acidity regulators, opacifiers, stabilising agents, buffering agents, flavourings, sweeteners, colouring agents, and preservatives. For example, the preferred solid formulations of the present invention may be prepared as lozenges by heating the lozenge base (eg a mixture of sugar and liquid glucose) under vacuum to remove excess water and the remaining components are then blended into the mixture. The resulting mixture is then drawn into a continuous cylindrical mass from which the individual lozenges are formed. The lozenges are then cooled, subjected to a visual check and packed into suitable packaging. One form of suitable packaging is a blister pack of a water-impermeable plastics material (eg polyvinylchloride) closed by a metallic eg aluminium foil. The patient removes the lozenge by applying pressure to the blister to force the lozenge to rupture and pass through the metal foil seal. Lozenges will normally be sucked by the patient to release the flurbiprofen.
The preferred formulations for use in the present invention are compositions which can be sucked by the patient and which slowly release the flurbiprofen. The flurbiprofen then passes over the mucous membrane of the throat where some is absorbed providing topical relief. The unabsorbed flurbiprofen is then ingested by the patient and absorbed into the blood stream.
The flurbiprofen so absorbed can act systematically to provide analgesia, anti-inflammatory and anti-pyretic activity in addition to the relief that comes from the topical application of flurbiprofen to the mucous membrane of the throat.
The invention will be illustrated by the following Examples which are given by way of example only.
Examples 1 to 4 Lozenges were prepared containing the following ingredients expressed as the weight in miiligrammes per lozenge.
Ex1 E2 Ex3 Ex4 Racemic flurbiprofen 2.5 5 8.75 12.5 Flavouring (cherry) 7.05 7.05 7.05 7.05 Calcium carbonate 7.5 7.5 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.75 0.938 0.94 1.5 Solids from a 1:1 mixture of sugar to to to to and liquid glucose 2350 2350 2350 2350 The mixture of the sugar and liquid glucose was heated to 140oand a vacuum applied to reduce the water content of the mixture. The flavouring was added in a sealed vessel. The flurbiprofen, silicon dioxide (flow aid) and calcium carbonate were blended and the blend added to the remainder of the ingredients. The resulting mixture was cooled and formed into a continuous cylindrical mass from which the individual lozenges were formed. The individual solid lozenges were visually inspected and then packed.
The resulting lozenges were found to provide palatable, stable and effective treatment for sore throats.
* Trade mark Examples 5 to 7 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the 5 weight in milligrammes per lozenge.
Ex 5 Ex 6 Ex7 Racemic flurbiprofen 5 8.75 12.5 Levomenthol 4 4 4 Flavouring (orange) 1.645 1.645 1.645 Flavouring (grapefruit) 2.5 2.5 2.5 Sodium saccharin 2 2 2 Calcium Carbonate 7.5 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.22 1.5 Solids from a 1:1 mixture of sugar to to to and liquid glucose 2350 2350 2350 Examples 8 and 9 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the weight in milligrammes per lozenge.
Ex 8 Ex9 Racemic Flurbiprofen 5 12.5 Levomenthol 1.551 1.551 Flavouring (orange) 1.645 1.645 Peppermint Oil 2 2 Aspartame 4 4 Calcium Carbonate 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.5 Solids from a 1:1 mixture of sugar and to to liquid glucose 2350 2350 * Trade mark Examples 10 and 11 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the weight in milligrammes per lozenge.
Ex 10 Ex 11 Racemic Flurbiprofen 5 12.5 Levomenthol 4 4 Flavouring (orange) 1.645 1.645 Flavouring (lime) 2.5 2.5 Aspartame 4 4 Calcium Carbonate 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.5 Solids from a 1:1 mixture of sugar and to to liquid glucose 2350 2350 Examples 12 and 13 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the weight in milligrammes per lozenge.
Ex12 Ex 13 Racemic Flurbiprofen 5 12.5 Levomenthol 4 4 Flavouring (lime) 2.5 2.5 Aspartame 4 4 Calcium Carbonate 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.5 A 1:1 mixture of sugar and to to liquid glucose 2350 2350 * Trade mark The effectiveness of the treatment has been demonstrated by means of clinical trials in which patients suffering from sore throats are administered the formulations described in one of Examples 2, 3 and 4 or a placebo. The patient was asked to assess the effectiveness of the treatment on parameters such as the relief of the pain associated with the sore throat, the reduction in the swelling of the throat and/or the improvement in swallowing following treatment. The patients were also examined by a clinician to determine the amount of tonsillopharyngitis.
Examples 1 to 4 Lozenges were prepared containing the following ingredients expressed as the weight in miiligrammes per lozenge.
Ex1 E2 Ex3 Ex4 Racemic flurbiprofen 2.5 5 8.75 12.5 Flavouring (cherry) 7.05 7.05 7.05 7.05 Calcium carbonate 7.5 7.5 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.75 0.938 0.94 1.5 Solids from a 1:1 mixture of sugar to to to to and liquid glucose 2350 2350 2350 2350 The mixture of the sugar and liquid glucose was heated to 140oand a vacuum applied to reduce the water content of the mixture. The flavouring was added in a sealed vessel. The flurbiprofen, silicon dioxide (flow aid) and calcium carbonate were blended and the blend added to the remainder of the ingredients. The resulting mixture was cooled and formed into a continuous cylindrical mass from which the individual lozenges were formed. The individual solid lozenges were visually inspected and then packed.
The resulting lozenges were found to provide palatable, stable and effective treatment for sore throats.
* Trade mark Examples 5 to 7 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the 5 weight in milligrammes per lozenge.
Ex 5 Ex 6 Ex7 Racemic flurbiprofen 5 8.75 12.5 Levomenthol 4 4 4 Flavouring (orange) 1.645 1.645 1.645 Flavouring (grapefruit) 2.5 2.5 2.5 Sodium saccharin 2 2 2 Calcium Carbonate 7.5 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.22 1.5 Solids from a 1:1 mixture of sugar to to to and liquid glucose 2350 2350 2350 Examples 8 and 9 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the weight in milligrammes per lozenge.
Ex 8 Ex9 Racemic Flurbiprofen 5 12.5 Levomenthol 1.551 1.551 Flavouring (orange) 1.645 1.645 Peppermint Oil 2 2 Aspartame 4 4 Calcium Carbonate 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.5 Solids from a 1:1 mixture of sugar and to to liquid glucose 2350 2350 * Trade mark Examples 10 and 11 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the weight in milligrammes per lozenge.
Ex 10 Ex 11 Racemic Flurbiprofen 5 12.5 Levomenthol 4 4 Flavouring (orange) 1.645 1.645 Flavouring (lime) 2.5 2.5 Aspartame 4 4 Calcium Carbonate 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.5 Solids from a 1:1 mixture of sugar and to to liquid glucose 2350 2350 Examples 12 and 13 In a similar manner to that described in Examples 1 to 4 above, lozenges were made containing the following ingredients expressed as the weight in milligrammes per lozenge.
Ex12 Ex 13 Racemic Flurbiprofen 5 12.5 Levomenthol 4 4 Flavouring (lime) 2.5 2.5 Aspartame 4 4 Calcium Carbonate 7.5 7.5 Silicon Dioxide (Aerosil 300*) 0.94 1.5 A 1:1 mixture of sugar and to to liquid glucose 2350 2350 * Trade mark The effectiveness of the treatment has been demonstrated by means of clinical trials in which patients suffering from sore throats are administered the formulations described in one of Examples 2, 3 and 4 or a placebo. The patient was asked to assess the effectiveness of the treatment on parameters such as the relief of the pain associated with the sore throat, the reduction in the swelling of the throat and/or the improvement in swallowing following treatment. The patients were also examined by a clinician to determine the amount of tonsillopharyngitis.
Claims (4)
1. ~A suckable solid dosage form comprising 2.5 to 20 mg of flurbiprofen contained in a lozenge base formed by cooling a sugar-based or sugar alcohol-based molten mass, such that when the dosage form is administered to the oral cavity of a patient in need thereof and sucked the solid dosage form releases a therapeutically effective amount of flurbiprofen to the oral cavity so as to deliver said flurbiprofen to the surface of the throat of said patient for the treatment of sore throat.
2. ~A solid dosage form as claimed in claim 1 comprising 5 to 12.5 mg of flurbiprofen.
3. ~Use of flurbiprofen in the manufacture of a medicament for treating sore throat wherein the medicament is in the form of a suckable solid dosage form comprising 2.5 to 20 mg of flurbiprofen formed by cooling a sugar-based or sugar alcohol-based molten mass containing the flurbiprofen, so that on administering the dosage form to the oral cavity of a patient in need thereof, the solid dosage form releases a therapeutically effective amount of flurbiprofen to the oral cavity so as to deliver said flurbiprofen to the surface of the throat of said patient.
4. ~The use as claimed in claim 3 wherein the solid dosage form comprises to 12.5 mg of flurbiprofen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9523833.3 | 1995-11-22 | ||
| GBGB9523833.3A GB9523833D0 (en) | 1995-11-22 | 1995-11-22 | Medical treatment |
| PCT/EP1996/005208 WO1997018802A1 (en) | 1995-11-22 | 1996-11-21 | Pharmaceutical compositions comprising flurbiprofen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2238271A1 CA2238271A1 (en) | 1997-05-29 |
| CA2238271C true CA2238271C (en) | 2008-08-12 |
Family
ID=10784245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002238271A Expired - Fee Related CA2238271C (en) | 1995-11-22 | 1996-11-21 | Pharmaceutical compositions comprising flurbiprofen |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5889057A (en) |
| EP (1) | EP0862424B1 (en) |
| CN (1) | CN1148177C (en) |
| AT (1) | ATE252382T1 (en) |
| AU (1) | AU707749B2 (en) |
| BG (1) | BG64166B1 (en) |
| CA (1) | CA2238271C (en) |
| CZ (1) | CZ289643B6 (en) |
| DE (1) | DE69630460T2 (en) |
| DK (1) | DK0862424T3 (en) |
| ES (1) | ES2208768T3 (en) |
| GB (1) | GB9523833D0 (en) |
| HU (1) | HU225235B1 (en) |
| IL (1) | IL124568A0 (en) |
| NO (1) | NO317287B1 (en) |
| NZ (1) | NZ322933A (en) |
| PT (1) | PT862424E (en) |
| RU (1) | RU2203655C2 (en) |
| SK (1) | SK284092B6 (en) |
| UA (1) | UA46807C2 (en) |
| WO (1) | WO1997018802A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| GB9710521D0 (en) * | 1997-05-22 | 1997-07-16 | Boots Co Plc | Process |
| AU7916798A (en) * | 1997-05-22 | 1998-12-11 | Boots Company Plc, The | Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat |
| WO1998052540A1 (en) * | 1997-05-22 | 1998-11-26 | The Boots Company Plc | Pharmaceutical compositions |
| AU779783B2 (en) * | 1999-05-17 | 2005-02-10 | Eisai Inc. | Improved cellular uptake of bioactive agents |
| JP2003530437A (en) * | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Aβ42 lowering substance |
| WO2003041705A1 (en) * | 2001-11-13 | 2003-05-22 | Pharmacia Corporation | Oral dosage form of a sulfonamide prodrug such as parecoxib |
| US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
| ES2405287T3 (en) * | 2002-08-01 | 2013-05-30 | Eisai Inc. | Improved treatment of glutamine cancer |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Method and composition for treating neurodegenerative disorders |
| US20040265359A1 (en) * | 2003-04-17 | 2004-12-30 | Sacks Gordon S. | Oral delivery formulations of L-glutamine |
| WO2005065069A2 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| FR2865648B1 (en) * | 2004-02-03 | 2006-06-30 | Philippe Perovitch | METHOD FOR DIFFUSION OF INSOLUBLE MOLECULES IN AQUEOUS MEDIUM AND COMPOSITION IMPLEMENTING SAID METHOD |
| ITMI20040235A1 (en) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| US20050252144A1 (en) * | 2004-04-29 | 2005-11-17 | Macdonald Robert A | Veneers for walls, retaining walls and the like |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (en) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| GB2423710A (en) | 2005-03-01 | 2006-09-06 | Boots Healthcare Int Ltd | Lozenge production process |
| JP2009502807A (en) * | 2005-07-22 | 2009-01-29 | ミリアド ジェネティクス， インコーポレイテッド | Formulations and dosage forms with high drug content |
| WO2007055887A1 (en) * | 2005-11-02 | 2007-05-18 | Teikoku Pharma Usa, Inc. | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same |
| US7282224B1 (en) * | 2006-06-09 | 2007-10-16 | Guthy-Renker Corporation | Pain relief composition |
| EP2046119A2 (en) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| US7754234B2 (en) * | 2006-07-12 | 2010-07-13 | Jones Thomas L | Composition and method of treating a sore throat |
| US20080107747A1 (en) * | 2006-10-23 | 2008-05-08 | Roederer Joy E | Pain relief composition |
| BRPI0809430A2 (en) * | 2007-07-23 | 2014-09-09 | Teikoku Pharma Usa Inc | ORGANOLEPTICALLY ACCEPTABLE ORAL FORMULATIONS OF AN INDOL CEROTONIN RECEIVER AGONIST AND METHODS OF USE |
| MX2011012315A (en) | 2009-05-19 | 2011-12-16 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors. |
| IT1397132B1 (en) | 2009-12-01 | 2013-01-04 | Alfa Wassermann Spa | COMPOSITIONS INCLUDING NON-STEROID ANTI-INFLAMMATORS. |
| ES2660772T3 (en) * | 2010-11-15 | 2018-03-26 | Neuroderm Ltd | Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions therefor |
| GB201021267D0 (en) * | 2010-12-15 | 2011-01-26 | Reckitt Benckiser Healthcare Int Ltd | Novel pharmaceutical formulation |
| PL2854764T3 (en) | 2012-06-05 | 2019-07-31 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| GB201216893D0 (en) | 2012-09-21 | 2012-11-07 | Aesica Pharmaceuticals Ltd | Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen |
| PT3116475T (en) | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| CN110812331A (en) * | 2018-08-10 | 2020-02-21 | 北京普德康利医药科技发展有限公司 | Flurbiprofen pharyngeal retention particle |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1062721A (en) * | 1975-12-15 | 1979-09-18 | Anthony A. Sinkula | Propionic acid derivatives |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| JPH0647532B2 (en) * | 1983-08-31 | 1994-06-22 | ジ アツプジヨン カンパニ− | Treatment of alveolar bone resorption |
| AU6656886A (en) * | 1985-12-16 | 1987-06-18 | Cilag A.G. | Pharmaceutical composition of suprofen |
| EP0321505A1 (en) * | 1986-10-22 | 1989-06-28 | The Upjohn Company | Treatment of gingivitis with ibuprofen or flurbiprofen |
| JPS63156715A (en) * | 1986-12-19 | 1988-06-29 | Teisan Seiyaku Kk | Quick-acting slowly releasing agent |
| JP2540581B2 (en) * | 1988-02-04 | 1996-10-02 | 三省製薬株式会社 | Topical |
| US4931473A (en) * | 1989-02-15 | 1990-06-05 | Richardson-Vicks Inc. | Anesthetic oral compositions |
| DE69016665T3 (en) * | 1989-08-17 | 1999-01-14 | Sepracor Inc | ORAL S (+) - MEDIUM CONTAINING FLURBIPROFEN OR KETOPROFEN. |
| US5190981A (en) * | 1989-08-17 | 1993-03-02 | Sepracor Inc. | Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease |
| JP2738092B2 (en) * | 1989-11-17 | 1998-04-08 | ライオン株式会社 | Oral composition |
| JPH0426618A (en) * | 1990-05-21 | 1992-01-29 | Japan Tobacco Inc | Troche |
| IT1243342B (en) * | 1990-07-13 | 1994-06-10 | Farcon Ag | ORAL PHARMACEUTICAL COMPOSITIONS FOR LIQUID ANTI-INFLAMMATORY ACTIVITIES |
| DE4028906A1 (en) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | MEDICINAL PRODUCTS AND THEIR PREPARATION AND THEIR USE IN THE CONTROL OF PAIN AND / OR DEFENSE AND / OR FEVER OF ANIMALS AND PEOPLE |
| WO1994013280A1 (en) * | 1992-12-04 | 1994-06-23 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
| WO1994014476A1 (en) * | 1992-12-21 | 1994-07-07 | The Procter & Gamble Company | Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders |
| US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| ES2211916T3 (en) * | 1994-09-02 | 2004-07-16 | Virginia Commonwealth University | COMPOSITION TO RELIEF PAIN, CONTAINING A NON-NARCORTIC ANALGESIC AND AN ANALGESIC POTENTIATOR. |
| US5567733B1 (en) * | 1995-04-27 | 1999-08-24 | Jon G Dishler | Irritation relief using nonsteroidal anti-inflammatory compounds |
| JPH11508593A (en) * | 1995-07-05 | 1999-07-27 | ザ、プロクター、エンド、ギャンブル、カンパニー | Heating compound |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| ES2234010T3 (en) * | 1996-04-12 | 2005-06-16 | Novadel Pharma Inc. | POLAR ORAL SPRAY. |
-
1995
- 1995-11-22 GB GBGB9523833.3A patent/GB9523833D0/en active Pending
-
1996
- 1996-11-21 US US08/849,224 patent/US5889057A/en not_active Expired - Lifetime
- 1996-11-21 CA CA002238271A patent/CA2238271C/en not_active Expired - Fee Related
- 1996-11-21 SK SK665-98A patent/SK284092B6/en not_active IP Right Cessation
- 1996-11-21 AT AT96939925T patent/ATE252382T1/en active
- 1996-11-21 NZ NZ322933A patent/NZ322933A/en not_active IP Right Cessation
- 1996-11-21 HU HU0000180A patent/HU225235B1/en not_active IP Right Cessation
- 1996-11-21 EP EP96939925A patent/EP0862424B1/en not_active Expired - Lifetime
- 1996-11-21 DE DE69630460T patent/DE69630460T2/en not_active Expired - Lifetime
- 1996-11-21 WO PCT/EP1996/005208 patent/WO1997018802A1/en active IP Right Grant
- 1996-11-21 DK DK96939925T patent/DK0862424T3/en active
- 1996-11-21 PT PT96939925T patent/PT862424E/en unknown
- 1996-11-21 UA UA98063236A patent/UA46807C2/en unknown
- 1996-11-21 ES ES96939925T patent/ES2208768T3/en not_active Expired - Lifetime
- 1996-11-21 AU AU26119/97A patent/AU707749B2/en not_active Expired
- 1996-11-21 CN CNB96199729XA patent/CN1148177C/en not_active Expired - Lifetime
- 1996-11-21 IL IL12456896A patent/IL124568A0/en not_active IP Right Cessation
- 1996-11-21 RU RU98111594/14A patent/RU2203655C2/en active
- 1996-11-21 CZ CZ19981565A patent/CZ289643B6/en not_active IP Right Cessation
-
1998
- 1998-05-20 NO NO19982294A patent/NO317287B1/en not_active IP Right Cessation
- 1998-06-09 BG BG102526A patent/BG64166B1/en unknown
-
1999
- 1999-01-04 US US09/224,357 patent/US6166083A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| SK66598A3 (en) | 1998-12-02 |
| RU2203655C2 (en) | 2003-05-10 |
| BG64166B1 (en) | 2004-03-31 |
| US5889057A (en) | 1999-03-30 |
| EP0862424B1 (en) | 2003-10-22 |
| CA2238271A1 (en) | 1997-05-29 |
| GB9523833D0 (en) | 1996-01-24 |
| BG102526A (en) | 1999-02-26 |
| IL124568A0 (en) | 1998-12-06 |
| CN1207677A (en) | 1999-02-10 |
| NZ322933A (en) | 2000-02-28 |
| WO1997018802A1 (en) | 1997-05-29 |
| PT862424E (en) | 2004-02-27 |
| CN1148177C (en) | 2004-05-05 |
| DE69630460D1 (en) | 2003-11-27 |
| HUP0000180A3 (en) | 2001-10-29 |
| EP0862424A1 (en) | 1998-09-09 |
| ES2208768T3 (en) | 2004-06-16 |
| DK0862424T3 (en) | 2003-12-29 |
| NO317287B1 (en) | 2004-10-04 |
| DE69630460T2 (en) | 2004-08-19 |
| US6166083A (en) | 2000-12-26 |
| HUP0000180A2 (en) | 2000-08-28 |
| AU707749B2 (en) | 1999-07-22 |
| HU225235B1 (en) | 2006-08-28 |
| CZ156598A3 (en) | 1998-08-12 |
| NO982294L (en) | 1998-07-20 |
| ATE252382T1 (en) | 2003-11-15 |
| NO982294D0 (en) | 1998-05-20 |
| CZ289643B6 (en) | 2002-03-13 |
| SK284092B6 (en) | 2004-09-08 |
| UA46807C2 (en) | 2002-06-17 |
| AU2611997A (en) | 1997-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2238271C (en) | Pharmaceutical compositions comprising flurbiprofen | |
| EP0983059B1 (en) | Process for making flurbiprofen lozenges | |
| US4446140A (en) | Method and composition for treating mouth pain | |
| KR20100063124A (en) | Sustained release dosage forms for delivery of agents to an oral cavity of a user | |
| RU98111594A (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN | |
| US5190981A (en) | Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease | |
| US20220008331A1 (en) | Pharmaceutical compositions comprising flurbiprofen | |
| JP2704721B2 (en) | Ibuprofen formulation | |
| EP0315332B1 (en) | Antitussive liquid compositions containing phenol | |
| JP4824954B2 (en) | Oral composition for the treatment of stomatitis | |
| JPH0761933B2 (en) | Oral composition | |
| US5874065A (en) | Oral anti-acid paste and methods of use | |
| US5039526A (en) | Buccal lozenge for fluoride ion medication | |
| US20180228832A1 (en) | Stomatological composition containing nsaid or heparin compound | |
| JP2015178462A (en) | Oral rinsing agent of ibuprofen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151123 |
|
| MKLA | Lapsed |
Effective date: 20151123 |